Abstract
Background The COVID-19 is spreading worldwide, early non-pharmaceutical Interventions (NPIs) is crucial for mitigating COVID-19 epidemic. We aim to evaluate the impact of containment measures and the epidemic features of COVID-19 under social NPIs in Mainland China.
Methods Under the effective social NPIs, the spreading pattern of COVID-19 in China has changed into mostly clustered intra-household or intro-acquaintance transmission, and we established a stochastic NPIs model, named ScEIQRsh to fit the epidemic and NPIs data of each province in China.
Results This ScEIQRsh model could be well fitted with both the reported number of accumulative confirmed cases and epidemiological survey (EPS)-based quarantined cases of each province in China. We found that the median transmission rate of COVID-19 among acquaintances was 10.22 (IQR 8.47, 12.35) across Mainland China and the COVID-19 spreading was prevented by NPIs implementation within 25-30 days. Among NPIs, measures to diminish contactable susceptible (Sc), such as staying home, travel constraint etc. and measures to avoid delay of diagnosis and hospitalized isolation (η) were more effective than EPS-based quarantine (κ,ρ or surveyQ). Upon the fitted models, the proportion of asymptomatic infectors was determined to be 14.88% (IQR 8.17%, 25.37%). The median incubation period and communicable period of COVID-19 under NPIs were 4.16 (IQR 3.60, 4.71) and 6.77 (IQR 4.53, 10.36) days respectively, and the median time from exposed to being contagious was 2.39 (IQR 2.26, 2.56) days. Besides, we identified that the optimal temperature for COVID-19 spreading was in the range of 5°C-14°C.
Conclusion This study provided useful suggestions about NPI strategy for the prevention of COVID-19 spreading, which should be helpful for the control of COVID-19, as well as other similar infectious disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵† Joint correspondence authors
Data Availability
No additional data avaiable.
